TD Cowen Maintains Buy on Elevance Health, Lowers Price Target to $484
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Ryan Langston maintains a Buy rating on Elevance Health but lowers the price target from $589 to $484.

October 21, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
TD Cowen's analyst Ryan Langston maintains a Buy rating on Elevance Health but reduces the price target from $589 to $484, indicating a more conservative outlook.
The maintained Buy rating suggests continued confidence in Elevance Health's prospects, but the lowered price target reflects a more cautious stance on its valuation. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100